Limits...
Label-free detection of rare cell in human blood using gold nano slit surface plasmon resonance.

Mousavi MZ, Chen HY, Hou HS, Chang CY, Roffler S, Wei PK, Cheng JY - Biosensors (Basel) (2015)

Bottom Line: The suspension containing the captured cells (MNPs-cells) is then introduced into a microfluidic chip integrated with a gold nanoslit film.MNPs-cells bind with the second specific antibody immobilized on the surface of the gold nanoslit and are therefore captured on the sensor active area.The cell binding on the gold nanoslit was monitored by the wavelength shift of the SPR spectrum generated by the gold nanoslits.

View Article: PubMed Central - PubMed

Affiliation: Research Center for Applied Sciences, Academia Sinica, Taipei 11529, Taiwan. m.mousavi07@gmail.com.

ABSTRACT
Label-free detection of rare cells in biological samples is an important and highly demanded task for clinical applications and various fields of research, such as detection of circulating tumor cells for cancer therapy and stem cells studies. Surface Plasmon Resonance (SPR) as a label-free method is a promising technology for detection of rare cells for diagnosis or research applications. Short detection depth of SPR (400 nm) provides a sensitive method with minimum interference of non-targets in the biological samples. In this work, we developed a novel microfluidic chip integrated with gold nanoslit SPR platform for highly efficient immunomagnetic capturing and detection of rare cells in human blood. Our method offers simple yet efficient detection of target cells with high purity. The approach for detection consists of two steps. Target cells are firs captured on functionalized magnetic nanoparticles (MNPs) with specific antibody I. The suspension containing the captured cells (MNPs-cells) is then introduced into a microfluidic chip integrated with a gold nanoslit film. MNPs-cells bind with the second specific antibody immobilized on the surface of the gold nanoslit and are therefore captured on the sensor active area. The cell binding on the gold nanoslit was monitored by the wavelength shift of the SPR spectrum generated by the gold nanoslits.

Show MeSH

Related in: MedlinePlus

A schematic of DCM. (a) The first step includes: (i) Functionalizing the MNPs with antibody I; (ii) Mixing the functionalized MNPs (carrying antibody I) with the sample to capture the target cells. (b) The second step includes introducing the mixture of blood sample and MNPs to the microfluidic chip and capturing the MNPs-cells to binds to the antibody II on the gold nanoslits. The cell binding on the gold nanoslits was monitored by the wavelength shift of the SPR spectrum generated by the gold nanoslits. The detection area of the nanoslits is defined by the focal spot of the probe light.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4384085&req=5

biosensors-05-00098-f001: A schematic of DCM. (a) The first step includes: (i) Functionalizing the MNPs with antibody I; (ii) Mixing the functionalized MNPs (carrying antibody I) with the sample to capture the target cells. (b) The second step includes introducing the mixture of blood sample and MNPs to the microfluidic chip and capturing the MNPs-cells to binds to the antibody II on the gold nanoslits. The cell binding on the gold nanoslits was monitored by the wavelength shift of the SPR spectrum generated by the gold nanoslits. The detection area of the nanoslits is defined by the focal spot of the probe light.

Mentions: The double capturing method (DCM) is based on two specific capturing steps of cancer cells. The schematic of DCM is shown in Figure 1. In the first step (Figure 1a), the functionalized MNPs immobilized with the first antibody that is specific for target cell surface receptors (antibody I) isolates the cancer cells from the sample. In the second step, the isolated cancer cells on the MNPs (MNPs-cells) are binding to the immobilized antibody (the second antibody, antibody II) on the gold nanoslit surface. The cell binding is detected by monitoring the shift of SPR spectrum produced by gold nanoslits. Antibody I and antibody II were selected to achieve high specific capturing of the target cells from the blood sample. The two steps are described in detail as follows.


Label-free detection of rare cell in human blood using gold nano slit surface plasmon resonance.

Mousavi MZ, Chen HY, Hou HS, Chang CY, Roffler S, Wei PK, Cheng JY - Biosensors (Basel) (2015)

A schematic of DCM. (a) The first step includes: (i) Functionalizing the MNPs with antibody I; (ii) Mixing the functionalized MNPs (carrying antibody I) with the sample to capture the target cells. (b) The second step includes introducing the mixture of blood sample and MNPs to the microfluidic chip and capturing the MNPs-cells to binds to the antibody II on the gold nanoslits. The cell binding on the gold nanoslits was monitored by the wavelength shift of the SPR spectrum generated by the gold nanoslits. The detection area of the nanoslits is defined by the focal spot of the probe light.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4384085&req=5

biosensors-05-00098-f001: A schematic of DCM. (a) The first step includes: (i) Functionalizing the MNPs with antibody I; (ii) Mixing the functionalized MNPs (carrying antibody I) with the sample to capture the target cells. (b) The second step includes introducing the mixture of blood sample and MNPs to the microfluidic chip and capturing the MNPs-cells to binds to the antibody II on the gold nanoslits. The cell binding on the gold nanoslits was monitored by the wavelength shift of the SPR spectrum generated by the gold nanoslits. The detection area of the nanoslits is defined by the focal spot of the probe light.
Mentions: The double capturing method (DCM) is based on two specific capturing steps of cancer cells. The schematic of DCM is shown in Figure 1. In the first step (Figure 1a), the functionalized MNPs immobilized with the first antibody that is specific for target cell surface receptors (antibody I) isolates the cancer cells from the sample. In the second step, the isolated cancer cells on the MNPs (MNPs-cells) are binding to the immobilized antibody (the second antibody, antibody II) on the gold nanoslit surface. The cell binding is detected by monitoring the shift of SPR spectrum produced by gold nanoslits. Antibody I and antibody II were selected to achieve high specific capturing of the target cells from the blood sample. The two steps are described in detail as follows.

Bottom Line: The suspension containing the captured cells (MNPs-cells) is then introduced into a microfluidic chip integrated with a gold nanoslit film.MNPs-cells bind with the second specific antibody immobilized on the surface of the gold nanoslit and are therefore captured on the sensor active area.The cell binding on the gold nanoslit was monitored by the wavelength shift of the SPR spectrum generated by the gold nanoslits.

View Article: PubMed Central - PubMed

Affiliation: Research Center for Applied Sciences, Academia Sinica, Taipei 11529, Taiwan. m.mousavi07@gmail.com.

ABSTRACT
Label-free detection of rare cells in biological samples is an important and highly demanded task for clinical applications and various fields of research, such as detection of circulating tumor cells for cancer therapy and stem cells studies. Surface Plasmon Resonance (SPR) as a label-free method is a promising technology for detection of rare cells for diagnosis or research applications. Short detection depth of SPR (400 nm) provides a sensitive method with minimum interference of non-targets in the biological samples. In this work, we developed a novel microfluidic chip integrated with gold nanoslit SPR platform for highly efficient immunomagnetic capturing and detection of rare cells in human blood. Our method offers simple yet efficient detection of target cells with high purity. The approach for detection consists of two steps. Target cells are firs captured on functionalized magnetic nanoparticles (MNPs) with specific antibody I. The suspension containing the captured cells (MNPs-cells) is then introduced into a microfluidic chip integrated with a gold nanoslit film. MNPs-cells bind with the second specific antibody immobilized on the surface of the gold nanoslit and are therefore captured on the sensor active area. The cell binding on the gold nanoslit was monitored by the wavelength shift of the SPR spectrum generated by the gold nanoslits.

Show MeSH
Related in: MedlinePlus